Association of pretreatment SUV max of cervix and SCC‐antigen with FIGO2018 stage in Stage IIB–IVB squamous cervical cancer and relationship to prognosis

2020 ◽  
Vol 152 (1) ◽  
pp. 112-117
Author(s):  
Huafeng Shou ◽  
Yoshioka Yasuo ◽  
Shuhui Yuan ◽  
Hanmei Lou ◽  
Juan Ni
2018 ◽  
Vol Volume 10 ◽  
pp. 3177-3191
Author(s):  
Jinna Wu ◽  
Huanhuan Sun ◽  
Shuncong Wang ◽  
Yan Yan ◽  
Fengze Sun ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-20 ◽  
Author(s):  
Marina A. Senchukova ◽  
Elena V. Makarova ◽  
Elena I. Shurygina ◽  
Nadezhda N. Volchenko

The determination of factors associated with progression of cervical cancer is important, both for a recurrence risk assessment and for determining optimal treatment tactics. Previously, we showed the prognostic value of different types of tumor microvessels (MVs) in gastric and breast cancer. The object of this research was to study the morphology and clinical significance of different tumor microvessels in early cervical cancer. A total of 65 archived paraffin blocks of patients with I-IIA stages of squamous cervical cancer were investigated. Samples were stained with Mayer hematoxylin and immunohistochemically using antibodies to CD34, podoplanin, HIF-1a, and Snail. The eight types of tumor MVs differed in morphology were identified. It was established that only the dilated capillaries (DСs) with weak expression of CD34, the contact type DCs, the capillaries in tumor solid component, and the lymphatic vessels in the lymphoid and polymorphic cell infiltrates of tumor stroma are associated with clinical and pathological characteristics of early cervical cancer. Preliminary results also suggest that a combination of fragmentation in tumor solid component and the contact type DCs may predict a recurrence of early cervical cancer. Given the small number of cervical cancer recurrences, the predictive significance of the described markers requires a more thorough examination.


PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0156259 ◽  
Author(s):  
Christina S. Fjeldbo ◽  
Eva-Katrine Aarnes ◽  
Eirik Malinen ◽  
Gunnar B. Kristensen ◽  
Heidi Lyng

2018 ◽  
Vol 36 (16) ◽  
pp. 1548-1555 ◽  
Author(s):  
Sudeep Gupta ◽  
Amita Maheshwari ◽  
Pallavi Parab ◽  
Umesh Mahantshetty ◽  
Rohini Hawaldar ◽  
...  

Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. Patients and Methods This was a single-center, phase III, randomized controlled trial ( ClinicalTrials.gov identifier: NCT00193739). Eligible patients were between 18 and 65 years old and had stage IB2, IIA, or IIB squamous cervical cancer. They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks. Patients in the neoadjuvant group received postoperative adjuvant radiation or concomitant chemotherapy and radiotherapy, if indicated. The primary end point was disease-free survival (DFS), defined as survival without relapse or death related to cancer, and secondary end points included overall survival and toxicity. Results Between September 2003 and February 2015, 635 patients were randomly assigned, of whom 633 (316 patients in the neoadjuvant chemotherapy plus surgery group and 317 patients in the concomitant chemoradiation group) were included in the final analysis, with a median follow-up time of 58.5 months. The 5-year DFS in the neoadjuvant chemotherapy plus surgery group was 69.3% compared with 76.7% in the concomitant chemoradiation group (hazard ratio, 1.38; 95% CI, 1.02 to 1.87; P = .038), whereas the corresponding 5-year OS rates were 75.4% and 74.7%, respectively (hazard ratio, 1.025; 95% CI, 0.752 to 1.398; P = .87). The delayed toxicities at 24 months or later after treatment completion in the neoadjuvant chemotherapy plus surgery group versus the concomitant chemoradiation group were rectal (2.2% v 3.5%, respectively), bladder (1.6% v 3.5%, respectively), and vaginal (12.0% v 25.6%, respectively). Conclusion Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer.


2012 ◽  
Vol 22 (1) ◽  
pp. 150-158 ◽  
Author(s):  
Karin Sundström ◽  
Alexander Ploner ◽  
Lisen Arnheim Dahlström ◽  
Juni Palmgren ◽  
Joakim Dillner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document